Does Lurbinectedin Harm Unborn Babies?
Lurbinectedin (Zepzelca), an alkylating agent used for small cell lung cancer, causes embryo-fetal toxicity in animal studies. It crosses the placenta and leads to fetal death, growth restriction, and developmental abnormalities like reduced skeletal ossification in rats and rabbits at doses below human equivalents.[1][2]
Pregnancy Category and Human Warnings
Classified as Pregnancy Category D by the FDA, indicating positive evidence of human fetal risk from past data, though controlled trials are absent due to ethical issues. The label warns of potential fetal harm; animal data show abortions, malformations, and decreased fertility. Women of childbearing potential must use effective contraception during treatment and for 6 months after the last dose. Men with partners of childbearing potential should use contraception for 4 months post-treatment.[1][3]
Mechanisms Behind Fetal Risks
As a DNA-binding agent, lurbinectedin inhibits cell proliferation, which is especially damaging during rapid embryonic division. It induces apoptosis and cell cycle arrest, disrupting organogenesis. Exposure in early pregnancy (first trimester) risks major malformations; later exposure may cause growth delays or preterm birth.[2][4]
What If Someone Gets Pregnant During Treatment?
Immediate discontinuation is advised, with consultation from an obstetrician. No specific antidote exists. Fetal monitoring via ultrasound is recommended, but outcomes vary—some pregnancies result in miscarriage, others in viable but compromised infants. Breastfeeding is contraindicated due to excretion in milk.[1][3]
Contraception and Fertility Impacts
Required contraception: hormonal, barrier, or intrauterine devices. Lurbinectedin impairs female fertility (ovarian atrophy in animals) and may cause male sterility via testicular damage. Cryopreservation of sperm or eggs is advised pre-treatment.[1][2]
Clinical Data and Real-World Reports
No dedicated human pregnancy studies exist. Post-marketing reports are limited but include spontaneous abortions and congenital anomalies consistent with alkylating agents. Oncologists weigh maternal benefits against fetal risks, often recommending termination counseling.[3][4]
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Pregnancy
[3]: Medscape - Zepzelca (Lurbinectedin) Warnings
[4]: PubMed - Embryotoxicity of Lurbinectedin